Skip to content

Evaluating Bubble-PAPR for Healthcare Workers

A Phase I Study of an 'In-house' Developed Prototype Powered Air Purifying Respirator (PAPR) for Use as Personal Protective Equipment (PPE) for Healthcare Workers (Bubble PAPR)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04681365
Acronym
BubblePAPR
Enrollment
106
Registered
2020-12-23
Start date
2021-02-24
Completion date
2021-12-31
Last updated
2022-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

This project will produce a low cost, ergonomic, hood integrated PAPR for use initially within the NHS. It will focus on user centred design, engineering optimisation, feasibility testing, certification and intellectual property protection. This study will evaluate the pre-CE marked Bubble PAPR prototype PPE in the clinical environment and gather usability data from consenting participants (staff).

Detailed description

Aim: To develop low cost, ergonomic, personal protective equipment to prevent virus transmission to NHS healthcare workers. This project aims to address these problems by taking a user centred design approach to develop and manufacture a highly functional Hood Integrated Personal Air Purifying Respirator (HI-PAPR) at a low cost. The design team brings together Manchester University NHS Foundation Trust (MFT) ICU frontline clinical staff, an experienced product design consultancy, Designing Science Limited (DSL) and the technical expertise of the School of Engineering at the University of Manchester (UoM). The project will run through a rapid design and evaluation cycle in simulated and clinical environments to refine the concept to meet regulatory requirements. The final product could be used in primary/secondary care and in the community and will be ready for wide-scale manufacture and supply for the UK NHS within six months of the project start. This study will evaluate Bubble PAPR in the clinical environment and gather usability data from frontline healthcare staff. We hypothesise that: * The Bubble PAPR will meet or exceed the British and European standards for PAPRs. * That participating staff who subsequently use the PAPR will rate the PPE as: * More comfortable than current PPE * Safer than current PPE * Easier to communicate with colleagues than current PPE * Easier to communicate with patients than current PPE Our research question is: • Do clinical staff report that the Bubble PAPR is more comfortable than current FFP3 facemasks.

Interventions

OTHERStaff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)

Staff will wear and evaluate the Bubble PAPR instead of usual PPE consisting of FFP3/N95 facemasks. This novel, non-CE marked prototype PPE is a Powered air Purifying Respirator and is used 'in house' (not approved for use outside of the Sponsor organisation)

Sponsors

University of Manchester
CollaboratorOTHER
Manchester University NHS Foundation Trust
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years

Inclusion criteria

Provision of informed consent; bedside clinical staff (medical, nursing, allied healthcare professional) who manage patients with COVID-19 disease during routine clinical duties.

Exclusion criteria

Refusal to participate; unable to, or unwilling to wear the Bubble PAPR

Design outcomes

Primary

MeasureTime frameDescription
The primary endpoint is that participating staff rate Bubble PAPR to be more comfortable than current PPE.1monthPrimary outcome measure is 'Comfort' as defined by Q17 of the questionnaire (Please indicate how comfortable the Bubble PAPR is) on a 7-point Likert scale bounded by 1 (very uncomfortable) through to 7 (very comfortable).

Secondary

MeasureTime frame
Staff rate Bubble PAPR as safer than current PPE1month
Staff rate Bubble PAPR as easier to communicate with colleagues than existing PPE1month
Staff rate Bubble PAPR as easier to communicate with patients than existing PPE1month

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026